NCT06411821 is a Phase 2 clinical trial of Ulixertinib in Histiocytic Neoplasms, sponsored by Memorial Sloan Kettering Cancer Center.

Who is sponsoring NCT06411821?

NCT06411821 is sponsored by Memorial Sloan Kettering Cancer Center.

What drugs are being tested in NCT06411821?

Interventions in NCT06411821: Ulixertinib.

What condition does NCT06411821 study?

NCT06411821 studies Histiocytic Neoplasms.

Is NCT06411821 still recruiting?

NCT06411821 is currently recruiting now. Last updated 27 May 2026.

Last reviewed 2026-05-27 · How we verify

NCT06411821

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 2 Trial of Ulixertinib for Patients With Histiocytic Neoplasms

Recruiting now Phase 2 Last updated 27 May 2026

What this trial tests

Phase 2 trial testing Ulixertinib in Histiocytic Neoplasms in 38 participants. Currently enrolling.

Timeline

7 May 2024

Primary endpoint
1 May 2027

1 May 2027

Quick facts

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	38
Start date	7 May 2024
Primary completion	1 May 2027
Estimated completion	1 May 2027
Sites	8 locations across United States

Drugs / interventions tested

Ulixertinib (ulixertinib) — full drug profile →

Conditions studied

Histiocytic Neoplasms — all drugs for Histiocytic Neoplasms →

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

12 and older, any sex, with Histiocytic Neoplasms. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

overall response rate
Time frame: 1 year
Best overall response by PET is defined as the best response, according to PRC, recorded from the first day of study treatment until disease progression, recurrence, or death. Complete response Normalization of all lesions' (target and nontarget) SUV to background SUVliver (or SUVbrain for brain lesions) Partial response ≥50% decrease from baseline in sum of SUVs of all target lesions relative to

Sponsor's own description

The researchers are doing this study is to find out whether ulixertinib is an effective and safe treatment for people with histiocytic neoplasms.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

RAF-independent MEK mutations drive refractory histiocytic neoplasms but respond to ERK inhibition.
Diamond EL, Emile JF, Fujino T, Haroche J, et al · · 2026 · cited 3× · PMID 41135521 · DOI 10.1016/j.ccell.2025.09.014
Histiocyte Society blueprint for non-Langerhans cell histiocytosis research: unraveling complex diseases through collaboration.
Hershkovitz-Rokah O, Abeykoon JP, Ravindran A, Goyal G. · · 2025 · cited 2× · PMID 41178439 · DOI 10.3324/haematol.2024.286479

Verify or expand the search:

Other trials of Ulixertinib

Trials testing the same drug.

NCT05985954 — Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in P · Phase 1 · recruiting
NCT05804227 — Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Gliomas · EARLY_PHASE1 · recruiting
NCT05221320 — Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies · Phase 2 · terminated
NCT04488003 — Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations · Phase 2 · terminated
NCT04145297 — Ulixertinib (BVD-523) and Hydroxychloroquine in Patients W Advanced MAPK-Mutated Gastrointestinal Adenocarcinomas · Phase 1 · completed

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06411821 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
Last refreshed: 27 May 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06411821.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing